For the year ending 2025-12-31, FHTX had $26,964K increase in cash & cash equivalents over the period. -$86,149K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -74,283 |
| Stock-based compensation expense | 10,399 |
| Depreciation and amortization expense | 3,332 |
| Loss on disposal of property and equipment | -31 |
| Gain on lease modification | 1,632 |
| Impairment of long-lived assets | 5,914 |
| Noncash lease expense | 4,206 |
| Accretion of discount on marketable securities | 1,926 |
| Prepaid expenses and other current assets | -2,827 |
| Accounts payable | 481 |
| Accrued expenses and other liabilities | 2,204 |
| Operating lease liabilities | -6,743 |
| Deferred revenue | -30,909 |
| Net cash used in operating activities | -86,099 |
| Purchases of property and equipment | 50 |
| Purchases of marketable securities | 131,247 |
| Proceeds from maturities of marketable securities | 243,337 |
| Net cash provided by (used in) investing activities | 112,040 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-Prefunded Warrants | 0 |
| Payments of public offering costs | 0 |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 483 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-At Market Offering | 540 |
| Net cash provided by financing activities | 1,023 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 26,964 |
| Cash, cash equivalents and restricted cash at beginning of period | 57,162 |
| Cash, cash equivalents and restricted cash at end of period | 84,126 |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)